Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China

Ipsen0 sitesFebruary 13, 2023

ConditionsAcromegaly

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Acromegaly
Sponsor: Ipsen
Primary Endpoint: Overall patient satisfaction with SSA treatment.
Status: Withdrawn
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The purpose of the protocol is to achieve an in-depth understanding of the current satisfaction status of somatostatin analogue (SSA) treatment for acromegaly through patient and physician surveys.

Registry

clinicaltrials.gov

Start Date

February 13, 2023

End Date

October 2023

Last Updated

3 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Ipsen

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•For Patients:
•Age 18 years or older
•Diagnosed with acromegaly
•Receiving current SSA injections for acromegaly treatment for at least 3 months
•Signed electronic Informed Consent Form (eICF)
•For Physicians:
•Licensed endocrinologists or neurosurgeons
•Having prescribed SSAs for at least five patients with acromegaly in the past 6 months
•Signed eICF

Exclusion Criteria

•Patients will not be included in the survey if they meet any of the following criteria:
•Patients who are not able to successfully complete the questionnaire independently
•Pregnant patients

Outcomes

Primary Outcomes

Overall patient satisfaction with SSA treatment.

Time Frame: During the whole study period (approximately 3 months).

To be assessed by four levels of satisfaction including very satisfied, satisfied, dissatisfied, and very dissatisfied

Secondary Outcomes

Patient satisfaction with symptom control of SSA treatment(During the whole study period (approximately 3 months).)
Patient satisfaction with frequency of administration of SSA treatment(During the whole study period (approximately 3 months).)
Patient satisfaction with injection site reactions of SSA treatment(During the whole study period (approximately 3 months).)
Physician satisfaction with symptom control of SSA treatment(During the whole study period (approximately 3 months).)
Physician satisfaction with convenience of administration of SSA treatment(During the whole study period (approximately 3 months).)
Patient satisfaction with convenience of administration of SSA treatment(During the whole study period (approximately 3 months).)
Physician satisfaction with frequency of administration of SSA treatment(During the whole study period (approximately 3 months).)
Physician satisfaction with adverse reactions to SSA treatment(During the whole study period (approximately 3 months).)
Patient satisfaction with mode of administration of SSA treatment(During the whole study period (approximately 3 months).)
Patient satisfaction with adverse reactions to SSA treatment(During the whole study period (approximately 3 months).)
Physician satisfaction with injection site reactions of SSA treatment(During the whole study period (approximately 3 months).)
Aspects of patient concern before initiating SSA treatment(During the whole study period (approximately 3 months).)
Physician overall satisfaction with SSA treatment.(During the whole study period (approximately 3 months).)
Physician satisfaction with mode of administration of SSA treatment(During the whole study period (approximately 3 months).)
Aspects of physician concern before prescribing SSA treatment(During the whole study period (approximately 3 months).)
Overall patient satisfaction with SSA treatment: satisfied versus dissatisfied with their SSA treatment.(During the whole study period (approximately 3 months).)